Therapeutic Implications of PPARγ in Human Osteosarcoma

Abstract EN

Osteosarcoma (OS) is the most common nonhematologic malignancy of bone in children and adults.

Although dysregulation of tumor suppressor genes and oncogenes, such as Rb, p53, and the genes critical to cell cycle control, genetic stability, and apoptosis have been identified in OS, consensus genetic changes that lead to OS development are poorly understood.

Disruption of the osteogenic differentiation pathway may be at least in part responsible for OS tumorigenesis.

Current OS management involves chemotherapy and surgery.

Peroxisome proliferator-activated receptor (PPAR) agonists and/or retinoids can inhibit OS proliferation and induce apoptosis and may inhibit OS growth by promoting osteoblastic terminal differentiation.

Thus, safe and effective PPAR agonists and/or retinoid derivatives can be then used as adjuvant therapeutic drugs for OS therapy.

Furthermore, these agents have the potential to be used as chemopreventive agents for the OS patients who undergo the resection of the primary bone tumors in order to prevent local recurrence and/or distal pulmonary metastasis.